GUY'S AND ST THOMAS' NHS FOUNDATION TRUST: Home Mechanical Ventilation (HMV) is used for patients with symptomatic hypoventilation, they are small devices that can be used at home at night time or during day, dependent upon

Data-sharing agreement from NHS Digital registers of approved data releases, 2014–2019. Evidence status: source reported.

Organisation: GUY'S AND ST THOMAS' NHS FOUNDATION TRUST
Source reference: DARS-NIC-35239-W2W9R-v0.13
Jurisdiction: England
Licence: Open Government Licence v3.0, subject to NHS England terms and exclusions

Register reference: DARS-NIC-35239-W2W9R-v0.13
Agreement period: not published to no end date published
For commercial purposes (as marked in the register): Not stated
Release files listed by NHS England: 1

Data approved

Office for National Statistics Mortality Data

Objective, as published

Home Mechanical Ventilation (HMV) is used for patients with symptomatic hypoventilation, they are small devices that can be used at home at night time or during day, dependent upon disease progression. There is a need for a long term study of the effects of HMV in patients with hypercapnic COPD, as there is a considerable morbidity, and mortality with frequent hospital admissions associated with this condition. There are also an increasing number of referrals of patients with hypercapnic COPD to units specialising in ventilatory support for consideration of HMV, yet there is no good evidence for the long term effectiveness of this therapy. For the purposes of this trial HMV is used for patients chronic end stage chronic obstructive pulmonary disease. The hypothesis of this study is that the HMV and home oxygen therapy (HOT) compared to HOT alone will reduce re-admission to hospital in COPD patients who remain persistently hypercapnic following an exacerbation requiring non invasive ventilation (NIV). The primary outcome is to evaluate admission free survival with comparison between HMV and HOT and HOT alone. This data will be analysed by time to event analyses. Duration of hospital admissions will be also analysed. If the trial shows a clinical benefit, it will be important to know if the addition of HMV in patients with hypercapnic COPD represents an optimal use of medical resources. Any additional health benefits have to be judged against the costs of resources required to…

Expected benefits, as published

There are over 3 million people in the UK suffering from COPD. Current costs are £800 million per year to the NHS for those that suffer from COPD, which equates to £1.3 million per 100,000. Exacerbations of COPD represent 1 in 5 hospital admissions with 25% of patients having evidence of respiratory failure at admission. Current evidence demonstrates that an average of 15% of COPD patients will die within 3 months of being admitted with an exacerbation, rising to 30% at 1 year in patients who have had a severe exacerbation requiring respiratory support. The data provided by NHS Digital will allow the study to provide extended mortality data for patients included in the trial to examine for an effect on long term mortality. The outcome of the analysis will provide further information for p…

Source: https://webarchive.nationalarchives.gov.uk/ukgwa/2019/https://digital.nhs.uk/binaries/content/assets/legacy/excel/2/1/releaseregister20171201_20180228.xlsx. Captured 2026-10-30.

Limitations: Agreement as recorded in an NHS Digital register of approved data releases (2014–2019), retrieved from the UK Government Web Archive. That register lists releases made in its period and the agreement's purpose statement as it then stood; it gives no agreement dates, and the agreement may have changed since. Imported only where a paper quotes a reference no current register holds.